Article Topic
Peptide therapies — popular, unproven, dangerous
Americans have become accustomed to taking peptides for for improved health, but unless they’ve undergone clinical trials and received FDA approval, there’s no way to establish a peptide’s safety or effectiveness.
[...]Photo gallery, Gilead Sciences v Pain Relief Rx et al
Photo gallery, Gilead Sciences v Pain Relief Rx et al Examples of suspect product purchased from pharmacy-to-pharmacy online platforms in December 2025 and January 2026. Descovy sold to a pharmacy in Florida; later listed on RxPost A bottle dispensed in New Jersey; allegedly listed on RxPost. A bottle allegedly returned to Gilead with an altered…
[...]June 15, 2026: Colorado becomes the second state given federal approval for Canadian drug importation program
Similar importation programs have been plagued with logistical hurdles, despite extensive funding of the efforts.
[...]Partnership for Safe Medicines statement on FDA authorization of Colorado’s Section 804 Importation Program
“Colorado is now poised to repeat Florida’s failed attempt to implement Canadian drug importation,” said PSM Executive Director Shabbir Imber Safdar. “Since beginning their program in 2019, Florida has spent $132 million and still not imported a single unit of medicine, proving that these bulk importation programs are not reducing drug costs for Americans.”
[...]Fake medicines in Mexico, November 2025 – May 2026
Americans buying prescription medicines in Mexico are overlooking widespread drug counterfeiting in the country, and as AFPs popularize medical tourism to lower costs, what happens in Mexico’s drug supply chain is even more of a problem for Americans.
[...]Prescription Drug Affordability Board Activity, April-May 2026
Prescription Drug Affordability Board Activity, April and May 2026 Activities Summary Maryland: In its April meeting, the Maryland PDAB set a UPL on Jardiance. In its May meeting, the board set a UPL on Ozempic. Virginia: Virginia’s governor vetoed the highly anticipated bills that would have established a PDAB in her state. Colorado: The PDAB provided…
[...]Case overview: Gilead Sciences v Pain Relief Rx, et al (2026 — ) – ongoing
Gilead Sciences has filed a complaint against Pain Relief Rx and other companies that it alleges sold diverted medicines on pharmacy to pharmacy marketplaces.
[...]Partnership for Safe Medicines Applauds FDA Action to Curb Unsafe Compounding of GLP-1 Medications
The Partnership for Safe Medicines strongly supports the Food and Drug Administration’s proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list. This action reflects sound science, sound law, and a clear-eyed commitment to patient safety. Full statement inside.
[...]Prescription Drug Affordability Board Activity, February-March 2026
Prescription Drug Affordability Board Activity, February and March 2026 Activities Summary Colorado: The PDAB did not meet in February or March. The next meeting was held April 3, 2026. Maryland: At its February meeting, the PDAB introduced a new board member and approved UPL frameworks for Ozempic and Trulicity. In March, it heard a briefing…
[...]Jimmie Wilson suffered acute liver failure after taking compounded weight loss shots
Jimmie Wilson suffered liver failure after being treated with compounded tirzepatide. She didn’t know she was taking any risks, or that compounded and name-brand drugs weren’t the same.
[...]